Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

Vaccine - Tập 36 - Trang 606-614 - 2018
Lisa A. Jackson1, Hana M. El Sahly2, Sarah George3, Patricia Winokur4, Kathryn Edwards5, Rebecca C. Brady6, Nadine Rouphael7, Wendy A. Keitel2, Mark J. Mulligan7, Robert L. Burton8, Aya Nakamura9, Jennifer Ferreria9, Moon H. Nahm8
1Kaiser Permanente Washington Health Research Institute, Seattle, WA, United States
2Departments of Molecular Virology & Microbiology and Medicine, Baylor College of Medicine, Houston, TX, United States
3Division of Infectious Diseases, Allergy, & Immunology, Saint Louis University School of Medicine, and St. Louis VA Medical Center, St. Louis, MO, United States
4University of Iowa and Iowa City VA Medical Center, Iowa City, IA, United States
5Vanderbilt Vaccine Research Program, Division of Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, United States
6Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States
7The Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Decatur, GA, United States
8Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States
9The Emmes Corporation, Rockville, MD, United States

Tài liệu tham khảo

Tomczyk, 2014, Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged >/=65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR Morb Mortal Wkly Rep, 63, 822

Bonten, 2015, Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults, N Engl J Med, 372, 1114, 10.1056/NEJMoa1408544

Greenberg, 2014, Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60–64 years of age, Vaccine, 32, 2364, 10.1016/j.vaccine.2014.02.002

Lazarus, 2011, A randomized study comparing combined pneumococcal conjugate and polysaccharide vaccination schedules in adults, Clin Infect Dis, 52, 736, 10.1093/cid/cir003

Pelton, 2015, Rethinking risk for pneumococcal disease in adults: the role of risk stacking, Open Forum Infect Dis, 2, ofv020, 10.1093/ofid/ofv020

Burton, 2012, Development of a fourfold multiplexed opsonophagocytosis assay for pneumococcal antibodies against additional serotypes and discovery of serological subtypes in Streptococcus pneumoniae serotype 20, Clin Vaccine Immunol, 19, 835, 10.1128/CVI.00086-12

Poolman, 2011, Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines, Expert Rev Vaccines, 10, 307, 10.1586/erv.11.8

Jackson, 2007, Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine, Vaccine, 25, 4029, 10.1016/j.vaccine.2007.02.062

Lode, 2011, Dose-ranging study of a single injection of pneumococcal conjugate vaccine (1 x, 2 x, or 4 x) in healthy subjects aged 70 years or older, Vaccine, 29, 4940, 10.1016/j.vaccine.2011.04.132

Moore, 2015, Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance, Lancet Infect Dis, 15, 301, 10.1016/S1473-3099(14)71081-3

CDC. Trends by Serotype Group, 1998-2015. https://www.cdc.gov/abcs/reports-findings/survreports/spneu-types.html. Last updated June 21, 2016. Last accessed June 22 2017.

Thông tin
Thông tin xuất bản

Vaccine

Tập 36

606-614

Thông tin tác giả